Stratos Wealth Partners’s Sarepta Therapeutics SRPT Stock Holding History

Stratos Wealth Partners’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-1,231	Closed	-$210K	–	1169
2020 Q4	$210K	Sell	1,231 -197	-14%	-$29.2K	0.01%	985
2020 Q3	$201K	Sell	1,428 -88	-6%	-$13.4K	0.01%	921
2020 Q2	$243K	Buy	+1,516	New	+$206K	0.01%	834
2020 Q1	–	Sell	-2,285	Closed	-$295K	–	1033
2019 Q4	$295K	Buy	+2,285	New	+$231K	0.01%	767
2018 Q4	–	Sell	-385	Closed	-$62K	–	2279
2018 Q3	$62K	Buy	+385	New	+$52.6K	﹤0.01%	1361
2018 Q2	–	Sell	-500	Closed	-$37K	–	2361
2018 Q1	$37K	Buy	+500	New	+$33.3K	﹤0.01%	1736

Other funds holding SRPT

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Stratos Wealth Partners's SRPT Position: Q1 2021 in Review

Stratos Wealth Partners sold out of Sarepta Therapeutics (SRPT) in Q1 2021, closing a stake of 1,231 shares — an estimated $210K sold.

Stratos Wealth Partners first reported a position in SRPT in Q1 2018 and held it in 6 quarters. The position peaked at $295K in Q4 2019. 366 funds tracked by Wall St. Rank hold SRPT as of Q1 2021.

Stratos Wealth Partners reported no remaining Sarepta Therapeutics position as of Q1 2021 after selling out during the quarter.
Stratos Wealth Partners sold 1,231 Sarepta Therapeutics shares in Q1 2021, an estimated $210K.
Stratos Wealth Partners first reported a position in Sarepta Therapeutics in Q1 2018 and held it in 6 quarters.
Stratos Wealth Partners's Sarepta Therapeutics position peaked at $295K in Q4 2019.
366 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2021.

Based on Stratos Wealth Partners's 13F filing for Q1 2021, filed 27 Apr 2021.